内容紹介
マンモグラフィ検診は科学的に死亡率減少効果の証明された検診方法であるが、高濃度乳房では精度が低下し弱点として認識される。受診者の不利益を最小化する目的で高濃度乳房を通知する法律が米国で施行されているが、対策型検診を中心とする我が国においては、超音波などの追加検査の有用性を見極めた上での導入が望ましく、社会体制の整備に取り組むことが必要である。
Mammography( MG) is the only proven method for breast cancer screening that reduces mortality, although it does not achieve sufficient accuracy in dense breasts. Dense breast notification law is enforced many states in USA, however, it is too early in Japan because there are no adjunctive modality that provide mortality reduction in breast cancer screening. Although ultrasonography( US) is one of the promising modality to support weak point of MG, we have to ascertain the efficacy of US for mortality reduction in average risk population and also have to work on the setup of the social system before introducing dense breast notification.
目次
Mammography( MG) is the only proven method for breast cancer screening that reduces mortality, although it does not achieve sufficient accuracy in dense breasts. Dense breast notification law is enforced many states in USA, however, it is too early in Japan because there are no adjunctive modality that provide mortality reduction in breast cancer screening. Although ultrasonography( US) is one of the promising modality to support weak point of MG, we have to ascertain the efficacy of US for mortality reduction in average risk population and also have to work on the setup of the social system before introducing dense breast notification.